We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.22B
1-Year Est. Return 242.83%
This Fund
S&P 500
This Quarter Est. Return
+6.49%
1 Year Est. Return
+242.83%
3 Year Est. Return
+1,579.88%
5 Year Est. Return
+1,852.28%
10 Year Est. Return
–
AUM
$542M
AUM Growth
-$452M
Cap. Flow
+$81.8M
Cap. Flow %
15.08%
Top 10 Hldgs %
65.43%
Holding
52
New
9
Increased
5
Reduced
6
Closed
8

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$39.9M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$24M
3
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
+$13M
4
TERN
Terns Pharmaceuticals
TERN
+$10.9M
5
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$8.66M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.26M
2
ACRS icon
Aclaris Therapeutics
ACRS
+$6.65M
3
COGT icon
Cogent Biosciences
COGT
+$6.61M
4
PANA.U
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
+$5.1M
5
FULC icon
Fulcrum Therapeutics
FULC
+$3.44M

Sector Composition

Rank Sector Weight
1 Healthcare 89.56%
2 Miscellaneous 8.94%
3 Financials 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
1
Nkarta
NKTX
$206M
$66.9M 12.35%
2,034,703
– –
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$49.2M 9.08%
3,168,388
– –
FMTX
3
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$43.9M 8.09%
1,565,529
+147,000
+10% +$5.3M
TIL icon
4
Instil Bio
TIL
$48.7M
$39M 7.19%
+77,701
New +$39.9M
STRO icon
5
Sutro Biopharma
STRO
$259M
$38.1M 7.03%
167,558
– –
NVAX icon
6
CALL
Novavax
NVAX
$1.54B
$36M 6.64%
+198,600
New +$39.6M
ACRS icon
7
Aclaris Therapeutics
ACRS
$783M
$25.8M 4.75%
1,022,612
-340,000
-25% -$6.65M
BOLT icon
8
Bolt Biotherapeutics
BOLT
$6.99M
$24.3M 4.48%
+36,873
New +$24M
ALLK
9
DELISTED
Allakos
ALLK
$16.8M 3.1%
146,259
– –
ICPT
10
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$14.8M 2.73%
640,688
+237,000
+59% +$6.61M
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$14.8M 2.72%
218,920
– –
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$14.7M 2.7%
2,372,476
– –
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
$12.5M 2.3%
169,852
-92,720
-35% -$7.26M
TERN
14
DELISTED
Terns Pharmaceuticals
TERN
$10.9M 2.02%
+497,555
New +$10.9M
ALLK
15
CALL
DELISTED
Allakos
ALLK
$9.53M 1.76%
+83,000
New +$10.5M
DBTX
16
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$9.39M 1.73%
+826,422
New +$13M
VRNA
17
DELISTED
Verona Pharma
VRNA
$9.29M 1.71%
1,111,112
– –
CVAC
18
DELISTED
CureVac
CVAC
$8.72M 1.61%
95,318
– –
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.69M 1.42%
+831,625
New +$8.66M
SYRE icon
20
Spyre Therapeutics
SYRE
$8.04B
$7M 1.29%
35,349
– –
BCEL
21
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$6.08M 1.12%
396,835
-78,108
-16% -$1.27M
TNGX icon
22
Tango Therapeutics
TNGX
$3.94B
$5.56M 1.03%
500,000
– –
NVAX icon
23
Novavax
NVAX
$1.54B
$5.47M 1.01%
30,160
– –
EQ icon
24
Equillium
EQ
$118M
$5.46M 1.01%
764,403
-309,882
-29% -$2.22M
JYAC
25
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.99M 0.92%
507,041
+501,818
+9,608% +$5.19M
1
2 3

Similar funds

MWA
Monograph Wealth Advisors Manhattan Beach, California $1.22B AUM 24.22% 1-Year Est. Return
SFP
Shepherd Financial Partners Winchester, Massachusetts $1.22B AUM 28.54% 1-Year Est. Return
OCM
Once Capital Management New York $1.22B AUM 87.6% 1-Year Est. Return
TCM
Tributary Capital Management Omaha, Nebraska $1.22B AUM 44.12% 1-Year Est. Return
TCM
Thames Capital Management Roseland, New Jersey $1.22B AUM 391.75% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.22B AUM 19.42% 1-Year Est. Return

Samsara BioCapital's Q1 2021 Portfolio in Review

As of Q1 2021, Samsara BioCapital held 52 positions worth $542M, down 45% from $994M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Samsara BioCapital deployed $81.8M of net new capital in Q1 2021, opening 9 new positions and adding to 5 existing holdings. Its largest new stake was Instil Bio: 77,701 shares worth $39M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 48% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $7.26M trimmed.

  • Samsara BioCapital's largest Q1 2021 buy was Instil Bio: 77,701 shares worth $39M.
  • Samsara BioCapital added most to Intercept Pharmaceuticals, Inc. in Q1 2021, an estimated $6.61M increase.
  • Samsara BioCapital's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $7.26M.
  • Samsara BioCapital fully exited Cogent Biosciences in Q1 2021, selling an estimated $6.61M.
  • Samsara BioCapital's ten largest holdings make up 65% of its $542M portfolio in Q1 2021.
  • Samsara BioCapital opened 9 new positions and closed 8 in Q1 2021.
  • Samsara BioCapital's portfolio value fell 45% quarter-over-quarter to $542M.

Based on Samsara BioCapital's 13F filing for Q1 2021, filed 18 May 2021.